Wednesday, July 8, 2026

Patent intelligence · US

US 6683069

Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin

expired A61KA61K2800/522A61K31/07A61K31/165
Status expired
Linked drugs 3
Pipeline programs 6
Years to expiry 0
Applicant portfolio 8,292
Patent details — US 6683069
Jurisdiction
US
Status
expired
Grant date
Jan 27, 2004
Expiration
Jan 22, 2024
Claims
26
CPC classes
A61K, A61K2800/522, A61K31/07, A61K31/165
View on Google Patents ↗

Quick answer

US 6683069 (Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin) is held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN. Status: expired. Granted Jan 27, 2004. Expires Jan 22, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
26
CPC classes
A61K, A61K2800/522, A61K31/07, A61K31/165, A61K31/167, A61K31/185

More from THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 6683069?

US 6683069 (Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin) is held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN. Status: expired. Granted Jan 27, 2004. Expires Jan 22, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6683069?

THE REGENTS OF THE UNIVERSITY OF MICHIGAN is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 6683069 expire?

Our index shows an expiration date of Jan 22, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.